CVS Health Corporation 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. CVS Health operates as an integrated health solutions company with four reportable segments: Health Care Benefits (Aetna), Health Services (CVS Caremark PBM, Oak Street Health, Signify Health), Pharmacy & Consumer Wellness (Retail), and Corporate/Other. As of year-end, the company operated approximately 9,000 retail locations, served over 37 million health insurance members, and managed a PBM network with approximately 87 million plan members.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $402,067 | $372,809 | +7.8% |
| Operating Income | $4,660 | $8,516 | -45.3% |
| Net Income (Attributable to CVS) | $1,768 | $4,614 | -61.7% |
| Adjusted Operating Income | $14,443 | $11,976 | +20.6% |
| Cash from Operations | $10,639 | $9,107 | +16.8% |
| Long-Term Debt | $60,502 | $60,527 | Flat |
| Cash & Equivalents | $8,453 | $8,586 | -1.6% |
Material Changes vs. Prior Period
- Significant Non-Recurring Charges: GAAP operating income declined primarily due to a $5.7 billion goodwill impairment in the Health Care Delivery reporting unit (Health Services segment), $1.2 billion in legacy litigation charges (related to Omnicare and PBM reporting practices), and $320 million in opioid litigation charges.
- Deconsolidation: The company recorded a $483 million gain on the deconsolidation of Omnicare, LLC, following its Chapter 11 bankruptcy filing in September 2025.
- Segment Performance:
- Health Care Benefits: Revenues increased 9.7% to $143.4 billion, driven by government business growth. Adjusted operating income improved significantly to $2.9 billion from $307 million in 2024.
- Health Services: Revenues increased 9.7% to $190.4 billion. GAAP operating income collapsed to $220 million due to the goodwill impairment, though Adjusted Operating Income remained relatively stable at $7.2 billion.
- Pharmacy & Consumer Wellness: Revenues increased 11.9% to $139.4 billion, driven by prescription volume growth (including Rite Aid acquisitions) and drug mix. Adjusted operating income rose 4.6% to $6.0 billion.
- Membership: Total medical membership decreased by 504,000 to 26.6 million, reflecting declines in individual exchange and government lines, partially offset by Commercial ASC growth.
Guidance, Outlook, and Risks
- Strategic Shifts: Management is reducing the pace of new primary care clinic openings and closing certain existing Oak Street Health clinics in 2026 to address utilization challenges and cost pressures.
- Regulatory Environment: The company faces heightened scrutiny regarding PBM practices, including FTC investigations and state-level legislation. The Inflation Reduction Act (IRA) continues to impact Medicare Part D economics, shifting more liability to plans.
- Medicare Rates: CMS proposed 2027 Medicare Advantage payment rates that, if finalized, would result in a negligible 0.09% revenue increase (excluding risk score trends), creating pressure on margins given rising medical costs.
- Legal Contingencies: The company maintains an accrual of approximately $4.0 billion for opioid litigation settlements. Additional litigation risks include False Claims Act actions regarding prescription processing and PBM remuneration reporting.
- Credit Ratings: Long-term debt ratings remain investment grade (BBB/Baa3), but Fitch and S&P have assigned a "Negative" outlook.
Key Facts for Investor Verification
- Goodwill Impairment Drivers: Verify the specific assumptions used in the discounted cash flow model for the Health Care Delivery unit that led to the $5.7 billion write-down, particularly regarding future clinic growth and utilization rates.
- Omnicare Liability: Confirm the extent of remaining joint and several liability for Omnicare penalties post-deconsolidation (currently $165 million accrued).
- Medical Benefit Ratio (MBR): Monitor the Health Care Benefits MBR, which improved to 91.2% in 2025, to assess underwriting performance against rising medical cost trends.
- Store Footprint: Track the execution of the retail store closure plan (243 stores closed in 2025) and its impact on same-store sales and operating leverage.
- Medicare Star Ratings: Verify the 2026 star ratings (81% of members in 4+ star plans) and their impact on 2027 bonus payments, as ratings declined slightly from 88% in the prior year.